文献速递姑息放疗与转移瘤

德国霍奇金研究组HD 16与HD 17试验中的放射治疗:现代霍奇金淋巴瘤的质量保证与剂量学分析

Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era.
PubMed 文献 · Adv Radiat Oncol · 2022-12-30

该分析评估德国霍奇金研究组HD16和HD17试验中放射治疗质量。HD16的84%放疗序列评为正确,显著优于前序研究(P<.001);HD17中累及淋巴结放疗(INRT)正确率为76.1%,累及野放疗(IFRT)为69.0%,亦优于既往研究(P<.001)。INRT与IFRT任何偏差和大偏差比例无显著差异(P=.418;P=.466)。

要点

  • HD16中84%放疗序列评为正确,显著优于前序研究(P<.001)。
  • HD17中INRT正确率76.1%,IFRT为69.0%,均优于既往研究(P<.001)。
  • INRT与IFRT任何偏差(P=.418)及大偏差(P=.466)比例无显著差异。

核心结论

  • GHSG最新一代研究显示放疗质量有所改善,现代INRT设计得以建立且质量未下降。
  • 在概念层面,需对合适的放疗技术进行个体化考虑。

研究设计与样本

  • 分析德国霍奇金研究组HD16和HD17试验的放疗计划,由GHSG参考放射肿瘤学专家组进行结构化的野设计评估和方案依从性评估。
  • HD17所有INRT计划均纳入分析,HD16和HD17分别纳入100份和50份IFRT计划进行分析。
  • HD16和HD17分别有100例和176例患者符合分析条件。

主要发现

  • HD16中84%的放疗序列评为正确,与前序研究相比有显著改善(P<.001)。
  • HD17中INRT病例的正确放疗设计比例为76.1%,IFRT病例为69.0%,优于既往研究(P<.001)。
  • INRT与IFRT比较,任何偏差比例无显著差异(P=.418),大偏差比例亦无显著差异(P=.466)。
  • 剂量学方面,INRT伴随甲状腺剂量改善。
  • HD17中比较不同放疗技术,调强放疗显示肺部高剂量减少,但以低剂量暴露增加为代价。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy (RT) is an integral part of treatment concepts for early-stage Hodgkin lymphoma. This analysis reports on RT quality in the recent HD16 and 17 trials of the German Hodgkin Study Group (GHSG). METHODS AND MATERIALS: All RT plans of involved-node radiation therapy (INRT) in HD 17 were requested for analysis, along with 100 and 50 involved-field radiation therapy (IFRT) plans in HD 16 and 17, respectively. A structured assessment regarding field design and protocol adherence was performed by the reference radiation oncology panel of the GHSG. RESULTS: Overall, 100 (HD 16) and 176 (HD 17) patients were eligible for analysis. In HD 16, 84% of RT series were evaluated as correct, with significant improvement compared with the predecessor studies (P < .001). In HD 17, 76.1% of INRT cases revealed a correct RT design compared with 69.0% of IFRT-cases, which was superior to previous studies (P < .001). Comparing INRT and IFRT, we found no significant differences in the percentage of any deviation (P = .418) or major deviations (P = .466). Regarding dosimetry, INRT was accompanied by an improvement in thyroid doses. Comparing different RT techniques, we found that intensity-modulated RT showed a reduction of high doses in the lung at the expense of an increased low-dose exposure in HD 17. CONCLUSIONS: The latest study generation of the GHSG demonstrates an improved quality in RT. A modern INRT design could be established without deterioration in quality. On a conceptual level, an individual consideration of the appropriate RT technique has to be performed.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Oertel M, Hering D, Nacke N, et al. Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era. Adv Radiat Oncol. 2022. PMID: 36896214. doi:10.1016/j.adro.2022.101169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。